Tuberculosis: a persistent global challenge

Tuberculosis (TB) remains a critical global health challenge, exacerbated by the COVID-19 pandemic, which has significantly disrupted TB control and increased mortality. Notably, the pandemic has diverted health resources and led to a dramatic 50% reduction in TB case detection in 2020, indirectly causing an estimated 400,000 additional TB deaths. This stark reduction in case detection likely underrepresents the true burden, as healthcare systems overwhelmed by COVID-19 have struggled to maintain effective TB diagnostics and treatment.
Historically, TB's global incidence peaked around 2003 but had shown a slow decline until the COVID-19 pandemic reversed these gains. The disease disproportionately affects low- and middle-income countries, straining under-resourced health systems. The highest disease burdens are observed in India and China, with sub-Saharan Africa experiencing the highest incidence rates and the countries of the former Soviet Union grappling with high levels of drug-resistant TB.
Innovations in TB management and control are urgently needed. The WHO End TB Strategy, which aimed for a 20% reduction in incidence between 2015 and 2020, fell short of its goals, highlighting the ongoing challenges in combating this disease. As TB continues to pose a significant health threat globally, sustained efforts and innovations in diagnostics, treatment, and control strategies are essential to mitigate its impact.